ASND250516C130000
- 17.10
- 0.000.00%
Ascendis Pharma A/S Newsroom
Ascendis Pharma Is Maintained at Outperform by RBC Capital
Ascendis Pharma Is Maintained at Outperform by Wedbush
Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group
Ascendis Pharma Analyst Ratings
Express News | Ascendis Pharma A/S : Leerink Partners Raises Target Price to $200 From $190
RBC Raises Price Target on Ascendis Pharma to $210 From $205, Keeps Outperform, Speculative Risk
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $212
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $194
ASCENDIS PHARMA Earnings Results: $ASND Reports Quarterly Earnings
Ascendis Pharma Q1 EPS $(1.66) Misses $(1.46) Estimate, Sales $106.16M Beat $94.64M Estimate
Earnings Flash (ASND) Ascendis Pharma A/S Reports Q1 Revenue EUR101M
Ascendis Pharma 1Q Loss/Shr EUR1.58 >ASND
Here Are the Major Earnings After the Close Today
Earnings Scheduled For May 1, 2025
A Glimpse of Ascendis Pharma's Earnings Potential
Ascendis Pharma A/S | 6-K: Report of foreign private issuer (related to financial reporting)
Earnings Preview: ASND to Report Financial Results Post-market on May 01
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading
Express News | Ascendis Pharma A/S : RBC Initiates Coverage With Outperform Rating; Price Target $205